Soft tissue liposarcomas (LPS) represent a heterogeneous group of malignancies derived from adipocytic tissue, accounting for approximately 20% of all adult soft tissue sarcomas. Their management has evolved significantly from a uniform, surgery-centric model to a complex, multidisciplinary, and histology-driven paradigm. This review outlines the contemporary therapeutic landscape, emphasizing the critical role of precise histopathological and molecular subtyping in guiding treatment decisions. We discuss the ongoing refinement of surgical and radiotherapeutic techniques, the subtype-specific efficacy of systemic therapies (including traditional chemotherapy, targeted agents like trabectedin and CDK4 inhibitors, and immunotherapy), and the integration of these modalities in both localized and advanced disease settings. The future direction lies in deepening molecular stratification, developing novel targeted therapies, and personalizing treatment algorithms through robust clinical trials and biomarker research. This article synthesizes current evidence to provide a framework for the modern, precision-based approach to liposarcoma care.

Liposarcoma, Well-Differentiated, Dedifferentiated, Myxoid, Pleomorphic, Multidisciplinary Treatment, Targeted Therapy, Trabectedin, MDM2, Precision Oncology.

Doyle, L. A. (2014). Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone. Cancer, 120(12), 1763–1774.

Gronchi, A., et al. (2021). Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 32(11), 1348–1365.

Demetri, G. D., et al. (2016). Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: A Randomized Clinical Trial. JAMA, 316(15), 1914–1924.

Dickson, M. A., et al. (2021). Phase II Trial of the CDK4 Inhibitor Palbociclib in Patients with Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma. Journal of Clinical Oncology, 39(30), 3397–3407.

Tap, W. D., et al. (2017). Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients with Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. JAMA, 323(13), 1266–1276.

Kawai, A., et al. (2020). The EORTC Soft Tissue and Bone Sarcoma Group: A history of clinical research contributing to improve the management of patients with soft tissue sarcoma. European Journal of Cancer, 127, 139-148.

Bonvalot, S., et al. (2022). STRASS (EORTC 1809): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma. Journal of Clinical Oncology, 40(17_suppl), LBA11501.

Schöffski, P., et al. (2020). Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. The Lancet, 387(10028), 1629-1637.

National Comprehensive Cancer Network (NCCN). (2023). NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Version 2.2023.

Keung, E. Z., et al. (2020). The immune microenvironment of soft tissue sarcomas: Implications for immunotherapy. Clinical Sarcoma Research, 10, 5.